Stealth BioTherapeutics Corp (MITO) ADR EACH REPR 12 ORD SHS SPON
Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. The Company is primarily focused on developing mitochondrial targeted therapies for diseases with clear unmet medical needs including cardiovascular, renal, neurodegenerative and metabolic diseases. The Company is engaged in developing its product pipelines, which include Elamipretide, SBT-20 and SBT-272.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.